eligibility_summary
Adults ≥18 with CLL/SLL and biopsy‑proven RT to DLBCL, ECOG 0–2. Cohorts: glofitamab mono (new/RR), +pola (untreated, later no BTKi), +pirtobrutinib (untreated+prior BTKi), +atezo (RR ≥1 prior). Adequate organ function. Exclude: Hodgkin variant, prohibited prior therapy/recent CAR‑T or IO, CNS disease, severe autoimmune or pneumonitis, serious infection or uncontrolled HIV/hepatitis, major cardiac/QT, neuropathy >G1 (pola), bleeding risk (pirtobrutinib), pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 trial in Richter’s transformation tests: 1) Glofitamab—CD20xCD3 T-cell–engaging bispecific humanized mAb (2:1 format) activating cytotoxic T cells against CD20+ B cells, 2) Polatuzumab vedotin—anti-CD79b antibody-drug conjugate delivering MMAE (microtubule inhibitor), 3) Pirtobrutinib—oral, selective, noncovalent BTK small-molecule inhibitor, 4) Atezolizumab—anti–PD-L1 immune checkpoint mAb. Obinutuzumab—type II anti-CD20 glycoengineered mAb—is used as lead-in, Tocilizumab—anti–IL-6R mAb—for CRS management. Targets/pathways: CD20 on B cells and CD3 on T cells (T-cell redirection), CD79b on B cells, BTK/BCR signaling, PD-1/PD-L1 axis, and IL-6/IL-6R inflammatory signaling.